Pliant Therapeutics, Inc.

NASDAQ:PLRX

Biotechnology

Healthcare
$0.81 -3.39%

-$0.04 today

Market cap
$50.14M
Beta
1.21
P/E (TTM)
-0.6
EPS (TTM)
-$1.83
52W Low $1.09High $1.95

Volume 0.15M

Average 0.49M

PLRX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Pliant Therapeutics, Inc.NASDAQ: PLRX

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2023
-10211.1%
Year-over-year change
-8937.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How PLRX compares with its peers on the latest reported figures

PLRX Competitors Peer median
Net Margin for PLRX and competitors
Company Period LTM level YoY 3-year change
MGNXMacroGenics, Inc.LTM Mar 2026-44.8% -8.2 pp+29.9 pp
STROSutro Biopharma, Inc.LTM Mar 2026-154.2% +214.9 pp-10.6 pp
COYACoya Therapeutics, Inc.LTM Mar 2026-266.1% +198.9 pp—
WHWKWhitehawk Therapeutics IncFY2025-288.3% -43.1 pp+109.4 pp
OVIDOvid Therapeutics Inc.LTM Mar 2026-339.3% +4217.8 pp+3364.5 pp
CLNNClene Inc.LTM Mar 2026-25009.7% -16703.7 pp-6761.3 pp
PLRXPliant Therapeutics, Inc.FY2025— ——
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
ZNTLZentalis Pharmaceuticals, Inc.FY2025— ——
GUTSFractyl Health, Inc. Common StockFY2025— ——
Peer median (excluding PLRX) -277.2%+95.4 pp+29.9 pp

Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.57M9.69M1.58M00
Cost of Revenue00001.7M
Gross Profit7.57M9.69M1.58M0(1.7M)
Gross Margin100.0%100.0%100.0%——
Research & Development77.55M96.94M127.8M169.31M109.16M
Selling, General & Admin27.56M39.95M57.93M59.06M47.22M
Operating Expenses105.11M136.89M185.73M228.37M148.38M
Depreciation & Amortization1.54M3.68M1.84M2.13M1.7M
EBITDA(95.73M)(118.85M)(158.23M)(205.16M)(145.09M)
EBITDA Margin-1264.2%-1227.1%-10014.4%——
Operating Income(97.54M)(127.2M)(184.15M)(228.37M)(150.07M)
Operating Margin-1288.1%-1313.4%-11654.7%——
Interest Income272K4.67M24.08M21.09M0
Interest Expense0791K1.27M3.02M2.56M
Other Income / Expenses272K3.88M22.81M18.06M729K
Income Before Tax(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Pre-Tax Margin-1284.5%-1273.3%-10211.1%——
Income Tax Expense00000
Net Income(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Net Margin-1284.5%-1273.3%-10211.1%——
EPS (Basic)(2.71)(2.94)(2.75)(3.47)(2.43)
EPS (Diluted)(2.71)(2.94)(2.75)(3.47)(2.43)
Weighted Avg Shares35.85M42.02M58.72M60.54M61.37M
Weighted Avg Shares (Diluted)35.85M42.02M58.72M60.54M61.37M

Pliant Therapeutics, Inc.

NASDAQ:PLRX

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.